Blood-based gene expression profiling in castrate-resistant prostate cancer

Castrate-resistant prostate cancer (CRPC), the most life-threatening form of prostate cancer, has recently been the focus of many successful new treatments. Contemporary trials highlight the heterogeneous prognosis of CRPC as overall survival times vary greatly across different patient sub-groups. A...

Descripción completa

Detalles Bibliográficos
Autor principal: Gross, Mitchell E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4568585/
https://www.ncbi.nlm.nih.gov/pubmed/26365516
http://dx.doi.org/10.1186/s12916-015-0463-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4568585/
https://www.ncbi.nlm.nih.gov/pubmed/26365516
http://dx.doi.org/10.1186/s12916-015-0463-8

Ejemplares similares